NovoCure Ltd Dossier
Qualitative Analysis
Business overview
NovoCure Ltd. is a Swiss-based global oncology company pioneering Tumor Treating Fields (TTFields), a non-invasive, anti-mitotic physical treatment modality that delivers low-intensity, alternating electric fields to disrupt cancer cell division. The company's proprietary wearable medical devices include Optune Gio (for glioblastoma), Optune Lua (for malignant pleural mesothelioma and non-small cell lung cancer), and Optune Pax (for locally advanced pancreatic cancer). Geographically, NovoCure derives the majority of its revenues from the United States, with additional commercial operations in Germany, France, Japan, and Greater China (via its partnership with Zai Lab).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding the Tumor Treating Fields (TTFields) technology beyond glioblastoma (GBM) into other solid tumor indications, including pancreatic cancer (Optune Pax) and non-small cell lung cancer (Optune Lua).
Expected impact: Aims to transition Novocure into a multi-indication oncology platform company, driving double-digit revenue growth and expanding the addressable patient population.
Streamlining operational expenses and implementing disciplined R&D spending to accelerate the company's path to profitability.
Expected impact: Expected to reduce residual operating expenses by approximately $60 million annually, offsetting growth investments and securing financial flexibility.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Grants Zai Lab an exclusive license to develop and commercialize TTFields therapy in Greater China (China, Hong Kong, Macau, and Taiwan), accelerating clinical trial enrollment and expanding market access.
Terms: Novocure received a $15 million upfront payment and is eligible for up to $78 million in development, regulatory, and commercial milestones, plus tiered royalties ranging from 10% to the mid-teens on net sales.
Collaborating to evaluate the combination of TTFields with Roche's anti-PD-L1 therapy, atezolizumab, in metastatic pancreatic ductal adenocarcinoma (mPDAC) through the Phase 2 PANOVA-4 trial.
Terms: Novocure acts as the study sponsor, and Roche provides atezolizumab for the trial.